LYEL Lyell Immunopharma, Inc.
P/E
--
Forward P/E
--
Price/Sales
8522.34
Beta
-0.032
Div Yield
--
Market Cap
--
Company Analysis
Latest News
Lyell Immunopharma reports 77% complete response rate for ronde-cel in third quarter 2026
Lyell reported a third quarter 2026 net loss of $45.5 million as it increased investments in its pivotal chimeric antigen receptor (CAR) T-cell therapy trials....
Lyell Immunopharma Announces $80 Million Private Placement of Common Stock
Lyell Immunopharma has entered into a Securities Purchase Agreement with institutional investors to raise approximately $80 million in gross proceeds through a...